Hengrui received clinical approval for many new drugs

On November 26, Hengrui issued an announcement that two clinical trial applications were approved by the National Food and Drug Administration: Carrelizumab combined with famitinib malate and paclitaxel for injection (albumin-bound) for the treatment of patients with advanced solid tumors An open, multi-center phase Ib/II clinical study; SHR-1701 injection combined with lenvatinib mesylate capsules vs.

Carrelizumab is a humanized anti-PD-1 monoclonal antibody that can bind to human PD-1 receptors and block the PD-1/PD-L1 pathway, restore the body’s anti-tumor immunity, and form cancer The basis of immunotherapy

Famitinib malate capsules are small molecule multi-target tyrosine kinase inhibitors

SHR-1701 can promote the activation of effector T cells, and at the same time can effectively improve the immune regulation in the tumor microenvironment, and ultimately effectively promote the immune system to kill tumor cells